Activity and safety of larotrectinib in adult patients with TRK fusion cancer: An expanded data set.

Alexander E. Drilon,Anna F. Farago,Daniel Shao-Weng Tan,Shivaani Kummar,Raymond S. McDermott,Jordan Berlin,Jyoti D. Patel,Marcia S. Brose,Serge Leyvraz,Makoto Tahara,Benjamin Maurice Solomon,John A. Reeves,Marc Mardoche Fellous,Nicoletta Brega,Barrett H. Childs,Ulrik Niels Lassen,David S. Hong

ONCOLOGY RESEARCH AND TREATMENT（2020）

引用 13|浏览26

暂无评分

摘要

3610Background: The highly selective TRK inhibitor larotrectinib is approved for the treatment of adult and pediatric cancers that harbor NTRK gene fusions; it achieves a 79% overall response rate ...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要